Dr. Todd Lanman implants first M6-C disc in 2-level study

Carly Behm -   Print  |
Listen
Text
  • Small
  • Medium
  • Large

Orthofix's M6-C artificial disc is being evaluated for contiguous two-level symptomatic cervical radiculopathy, according to an Aug. 2 news release.

Four things to know:

1. The first patient implant was completed by spine surgeon Todd Lanman, MD; 263 patients were enrolled in the study.

2. The FDA is conducting a U.S. Investigational Device Exemption study to compare the M6-C artificial disc and the anterior cervical discectomy and fusion for treating two-level symptomatic cervical radiculopathy.

3. Dr. Lanman said: "The M6-C artificial cervical disc two-level study will provide additional data to validate the effectiveness of disc replacement over fusion in patients suffering from degeneration in two contiguous levels." 

4. Previous long-term studies have shown patients who received the M6-C in an artificial cervical disc single-level clinical trial "continue to have statistically significant benefits at three and four years" compared to anterior cervical discectomy and fusion patients."

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

Featured Webinars

Featured Whitepapers

Featured Podcast